scholarly journals Brazilian Consensus Guidelines for Hematopoietic Stem Cell Transplantation - Inborn errors of metabolismo

JBMTCT ◽  
2021 ◽  
Vol 2 (4) ◽  
pp. 126
Author(s):  
Alessandra Araujo Gomes ◽  
Adriana Mello Rodrigues ◽  
Juliana Folloni Fernandes ◽  
Liane Daudt ◽  
Carmem Bonfim
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplantation ◽  
Inborn Errors ◽  
Hematopoietic Stem

Hematopoietic stem cell transplantation (HSCT) has the potential to cure a significant proportion of patients with malignant and nonmalignant diseases. The main rationale for HSCT in inborn errors of metabolism (IEM) is based on correcting the decreases enzymes by the donor cells within and outside the intravascular compartment. In this article, Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) provides a review of HSCT indications in IEM.

scholarly journals Estudio bibliométrico: 45 años de literatura biomédica en trasplante de células madre hematopoyéticas

Medunab ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 319-326
Author(s):  
Jenifer Vanessa Rios-Moreno ◽  
Silvia Juliana Bueno-Flórez ◽  
Diana Isabel Conde-Hurtado ◽  
Nick Tarazona ◽  
Claudia Lucía Sossa-Melo
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplantation ◽  
Hematopoietic Stem

Introducción: La bibliometría mide variables de la literatura científica que se describen de forma cuantitativa por medio de análisis estadístico; con esta herramienta se busca evidenciar el impacto de los trasplantes de células madre hematopoyéticas en la literatura de los últimos 45 años. Objetivo: Descripción de la literatura médica indexada en MEDLINE desde 1970 hasta 2015 sobre trasplantes de células madre hematopoyéticas. Metodología: Se realizó una búsqueda en la base de datos MEDLINE a través de GoPubMed y Fabumed. La estrategia de búsqueda fue: "Hematopoietic Stem Cell Transplantation"[Majr] AND "1970:2015"[dp]. Las variables analizadas fueron el número de publicaciones por año, revistas, países y porcentaje de publicaciones sobre trasplantes de células madre hematopoyéticas.  Resultados: Se recuperaron 23,295 referencias sobre trasplantes de células madre hematopoyéticas. Se identificaron 1,844 revistas diferentes, el mayor número de publicaciones se encontró en Bone Marrow Transplantation con 2,443 publicaciones, seguida de Blood con 1,375 y Biology of Bone Marrow Transplantation con 1,319 referencias. Estados Unidos fue el país con mayor número de publicaciones con 7,491 (32.15%); en Latinoamérica fueron publicados 324 (1.39%). Los descriptores de la literatura más investigados relacionados con el tema fueron: Trasplante de células madre hematopoyéticas con 23,345 publicaciones, humanos con 22,019 y células madre con 17,564. Conclusiones: Las publicaciones sobre trasplantes de células madre hematopoyéticas han incrementado de forma progresiva durante los 45 años estudiados. Los países desarrollados son los que han realizado mayor investigación del tema, en contraste con el número de publicaciones en total. [Rios-Moreno JV, Bueno-Florez SJ, Conde-Hurtado DI, Tarazona N, Sossa-Melo Claudia Lucía. Estudio bibliométrico: 45 años de literatura biomédica en trasplante de células madre hematopoyéticas. MedUNAB 2017-2018; 20(3): 319-326].  

scholarly journals Early complications in pediatric hematopoietic stem cell transplantation

JBMTCT ◽  
2021 ◽  
Vol 2 (4) ◽  
pp. 125
Author(s):  
Alessandra Araujo Gomes ◽  
Carla Nolasco Monteiro Breviglieri ◽  
Natalia Maria Tavares Ferreira Borges ◽  
Gabriele Zamperlini Netto
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplantation ◽  
Early Complications ◽  
Hematopoietic Stem

Hematopoietic stem cell transplantation (HSCT) has the potential to cure a significant proportion of patients with malignant and nonmalignant diseases, but the high doses of chemotherapy and/or radiotherapy included in conditioning regimens affect all organs and tissues. In this article, Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) provides a review of early complications in children undergoing HSCT.

scholarly journals Detection of Cells with Low Side Scatter and Dimmer CD45 Expression after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Good Survival

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3207-3207
Author(s):  
Yoshimitsu Shimomura ◽  
Hayato Maruoka ◽  
Yotaro Ochi ◽  
Yusuke Koba ◽  
Yuichiro Ono ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Cumulative Incidence ◽  
Marrow Transplantation ◽  
Hematopoietic Stem ◽  
Allogeneic Hsct

Abstract <Introduction> Hematogones are lymphoblast-like cells that increase transiently in the bone marrow and have a characteristic profile of normal B cell precursors co-expressing CD10 and CD19. A cluster of hematogones is often found in the region of low side scatter and dimmer CD45 expression (SSC low CD45 dim), which also includes lymphoid and myeloid precursors, basophils, and partial components of natural killer cells. However, in steady state healthy adult bone marrow, SSC low CD45 dim populations are hardly detectable. In the bone marrow of patients recovering from chemotherapy or bone marrow transplantation, SSC low CD45 dim populations occasionally appear, with the majority of the population consisting of hematogones, especially in patients in complete remission (CR). Studies have shown that increased hematogones in patients with high-risk hematological malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) improved survival. The specific detection of hematogones is difficult because multicolor flow cytometry is necessary to exclude myeloid/lymphoid blasts in active leukemia patients. However, after allogeneic HSCT in patients with leukemia and confirmed CR or malignant lymphoma without bone marrow invasion, hematogones can be easily detected as cells with SSC low CD45 dim populations. <Patients and methods> This retrospective case analysis included 88 patients treated with allogeneic HSCT at our hospitals from October 2010 to November 2014. The cases included acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in CR at the time of allogeneic HSCT, chemo-naïve or azacitidine-treated myelodysplastic syndrome (MDS) and malignant lymphoma (ML) or adult T cell leukemia/lymphoma (ATL) with marrow CR or without bone marrow invasion. We excluded 8 patients without engraftment. The remaining 80 patients underwent bone marrow aspiration around 28 days after HSCT and were confirmed to be in CR. Bone marrow cells were stained with APC-Cy7-conjugated CD45 and analyzed using FACSCanto. Patients were defined as being simply detected hematogones (SHG)-positive if 0.6%, which is the median proportion of SSC low CD45 dim cells in this study, or more of total nuclear cells were SSC low CD45 dim; the others were defined as SHG-negative. <Results> The median follow-up of survivors of our cohort was 773 (81-1593) days. Primary diagnoses were AML (n=36), ALL (n=21), MDS (n=8), and ML or ATL (n=15). They were treated with bone marrow transplantation (n=51), peripheral blood stem cell transplantation (n=6), and cord blood transplantation (n=23). Among them, 40 were SHG-positive and 40 were SHG-negative. Overall survivals (OS) at 2 years was 94.8% and 58.2% (p<0.001), event free survival (EFS) at 2 years was 94.9% and 46.5% (p<0.001). Cumulative incidence of relapse at 2 years was 5.1% and 34.0% (p<0.001), and cumulative incidence of treatment related mortality (TRM) at 2 years was 0% and 20.6% (p=0.0059) in SHG-positive and SHG-negative groups, respectively. Cumulative incidence of acute graft-versus-host disease (aGVHD) at day 100 was 68.3% and 65.5% (p=0.31) and for severe aGVHD (grade II-IV) was 31.8% and 36.3% (p=0.87) in SHG-positive and SHG-negative groups, respectively. Age ≥50 years, sex, hematopoietic cell transplant-comorbidity index over 2, disease risk index (DRI), myeloablative conditioning regimen and donor source were entered into multivariate analysis, which identified SHG-positive and a low or intermediate DRI as independently associated with a good prognosis. <Conclusion> Thus, the presence of SHG at day 28 predicts improved OS and EFS, and a lower incidence of relapse and TRM. This population of cells is easily detectable, providing useful information for outcome predictions. Patients without SSC low CD45 dim populations should be carefully observed after allogeneic HSCT. Disclosures No relevant conflicts of interest to declare.

scholarly journals Evaluation of early hospital discharge after allogeneic bone marrow transplantation for chronic myeloid leukemia

2007 ◽  
Vol 125 (3) ◽  
pp. 174-179 ◽  
Author(s):  
José Eduardo Nicolau ◽  
Leila Maria Magalhães Pessoa de Melo ◽  
Daniel Sturaro ◽  
Rosaura Saboya ◽  
Frederico Luiz Dulley
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Chronic Myeloid Leukemia ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Hematopoietic Stem

CONTEXT AND OBJECTIVE: The increasing number of patients waiting for bone marrow transplantation in our service led to the implement of an early hospital discharge program with the intention of reducing the interval between diagnosis and transplantation. In this study we analyzed the results from early discharge, with outpatient care for patients with chronic myeloid leukemia who underwent allogeneic bone marrow transplantation. DESIGN AND SETTING: Retrospective study at the Bone Marrow Transplantation Unit of Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo. METHODS: We compared clinical outcomes within 100 days post-transplantation, for 51 patients with chronic myeloid leukemia (CML) who received partially outpatient-based allogeneic hematopoietic stem cell transplantation, and the results were compared with a historical control group of 49 patients who received inpatient-based hematopoietic stem cell transplantation. RESULTS: There were significantly fewer days of hospitalization (p = 0.004), Pseudomonas-positive cultures (p = 0.006) and nausea and vomiting of grade 2-3 (p < 0.001) in the outpatient group. There were no significant differences in mortality between the groups and no deaths occurred within the first 48 days post-transplantation in the outpatient group. CONCLUSIONS: This partially outpatient-based hematopoietic stem cell transplantation program allowed an increased number of transplantations in our institution, in cases of CML and other diseases, since it reduced the median length of hospital stay without increasing morbidity and mortality.

scholarly journals Gestión del dolor de niños y adolescentes durante el período post- trasplante de células-tronco hematopoyéticas: una revisión integradora

2018 ◽  
Vol 18 (1) ◽  
pp. 535-581
Author(s):  
Graziele Caroline Cardoso de Sousa ◽  
Nen Nalú Alves das Mercês ◽  
Lara Adrianne Garcia Paiano da Silva ◽  
Alini Macedo
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Bone Marrow Transplantation ◽  
Pain Management ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Web Of Science ◽  
Hematopoietic Stem

Este estudo teve como objetivo identificar, em produções científicas, as estratégias utilizadas para o gerenciamento da dor de crianças e adolescentes no período pós-transplante de células-tronco hematopoéticas. Para tanto, utilizou-se como metodologia a revisão integrativa da literatura a partir das seguintes fontes de informação: MEDLINE, LILACS, ScIELO, BDENF, SCOPUS, Web of Science e Plataforma de periódicos CAPES. Os descritores utilizados para a busca foram: pain, pain management; pain pediatric; hematopoietic stem cell transplantation; bone marrow transplantation; e as siglas BMT e HSCT. A amostra final foi constituída por sete artigos científicos, com base nos critérios de inclusão e exclusão. As estratégias de gerenciamento da dor identificadas nos estudos foram: analgesia controlada pelo paciente, analgesia controlada pelo cuidador; terapias complementares, tais como: aromaterapia; fototerapia extra oral com diodos infravermelhos; aplicação de calor; crioterapia; música, jogos, massagem; e indicadores de resultados para monitorar a eficácia do gerenciamento da dor. Concluiu-se que as estratégias mais eficazes foram: analgesia controlada pelo paciente ou cuidador e o indicador de resultados que possibilitou o controle da dor em tempo hábil. Não obstante, é importante ressaltar que outros estudos são necessários para avaliar a eficácia das estratégias complementares citadas. Este estudio tuvo como objetivo identificar, en producciones científicas, las estrategias utilizadas en la gestión del dolor de niños y adolescentes durante el período post trasplante de células-tronco hematopoyéticas. Para ello, utilizó como metodología la revisión integradora de la literatura a partir de las siguientes fuentes de información: MEDLINE, LILACS, ScIELO, BDENF, SCOPUS, Web of Science y Plataforma de periódicos CAPES. Se utilizó como descriptores: pain, pain management; pain pediatric; hematopoietic stem cell transplantation; bone marrow transplantation; y las siglas BMT e HSCT. La muestra final fue constituida por siete artículos científicos, a partir de los criterios de inclusión y exclusión. Las estrategias para la gestión del dolor identificadas en los estudios fueron: analgesia controlada por el paciente, analgesia controlada por el cuidador; terapias complementarias, tales como: aromaterapia; fototerapia extra oral con diodos infrarrojos; aplicación de calor; crioterapia; música, juegos, masaje; e indicadores de resultados para medir la eficacia de la gestión del dolor. La conclusión es que las estrategias más eficaces fueron: analgesia controlada por el paciente o cuidador y el indicador de resultados que posibilitó el control del dolor en tiempo hábil. Sin embargo, es necesario hacer hincapié en la importancia de invertir en otros estudios para evaluación de la eficacia de dichas estrategias complementarias. This study aims at the identification of strategies used for pain management in children and teenagers during the hematopoietic stem cells post-transplant period. An integrative review of literature was employed as methodology for this work, using as sources of information the following databases: MEDLINE, LILACS, SCIELO, BDENF, SCOPUS, Web of Science and CAPES periodic portal. The terms used for searching were: pain, pain management, pain pediatric, hematopoietic stem cell transplantation, bone marrow transplantation; and the acronyms BMT and HSCT. The final sample comprised seven articles, based on inclusion and exclusion criteria. The identified strategies for pain management in the studies were: patient-controlled analgesia, caregiver-controlled analgesia; complementary therapies such as: aromatherapy, extra-oral phototherapy with infrared diodes, heat application, cryotherapy, music, games, massage; and results indicators, in order to monitor the pain management effectiveness. As a conclusion, the most effective strategies were: patient or caregiver-controlled analgesia, and the results indicators that allowed pain management in adequate time. Nevertheless, it is important to highlight that other studies are necessary to evaluate the effectiveness of the complementary strategies employed.

Sign in / Sign up

Export Citation Format

Share Document